SCHEMBL23788964

SCHEMBL23788964

Cc1cc(N(C)C)nc(Nc2ccc(NCCc3ccccc3)cc2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.69
TGM2 P21980 1/20 0.64
SLC2A1 P11166 4/20 0.60
KCNH2 Q12809 1/20 0.51
MAPT P10636 5/20 0.48
LMNA P02545 4/20 0.48
KDM4E B2RXH2 3/20 0.48
HTT P42858 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
USP2 O75604 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GPR55 Q9Y2T6 1/20 0.48
PLA2G1B P04054 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
KCNH3 Q9ULD8 3/20 0.46
DNM2 P50570 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TUBB4A P04350 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13329971 0.81 LMNA (0.64) TAAR1SLC2A1KCNH2MAPTLMNA
SCHEMBL3233135 0.80 MAPT (0.59) TAAR1TGM2SLC2A1MAPTLMNA
SCHEMBL23789082 0.78 TGM2 (1.00) TAAR1TGM2SLC2A1LMNAKDM4E
SCHEMBL12485120 0.77 TAAR1 (0.72) TAAR1TGM2SLC2A1KCNH2MAPT
SCHEMBL23788967 0.76 TGM2 (0.67) TAAR1TGM2SLC2A1MAPTLMNA
SCHEMBL23789090 0.76 TGM2 (0.73) TAAR1TGM2SLC2A1KCNH2MAPT
SCHEMBL23788970 0.75 TGM2 (0.78) TAAR1TGM2SLC2A1KCNH2MAPT
SCHEMBL23780651 0.74 TAAR1 (0.72) TAAR1TGM2SLC2A1KCNH2MAPT
SCHEMBL23788965 0.74 TGM2 (0.64) TAAR1TGM2SLC2A1KDM4EHTT
SCHEMBL3244336 0.73 MAPT (0.57) TAAR1TGM2SLC2A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276960-A1 INHIBITORS OF TISSUE TRANSGLUTAMINASE 2 (TG2) AND USES THEREOF NORTHWESTERN UNIVERSITY 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210276960-A1 INHIBITORS OF TISSUE TRANSGLUTAMINASE 2 (TG2) AND USES THEREOF TGM2, TGM3, TGM6 TAAR1 4661/4885TGM2 1/4885SLC2A1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.